Celltrion
http://
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Celltrion
SK Biopharm Moves Into Radiopharma Via $572m Full-Life Deal
After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.
Celltrion’s Xolair Biosimilar Reaches UK, Following Key US Filing
Celltrion has ticked off another major regulator as it continues to lead the pack of global developers for biosimilar Xolair.
AstraZeneca Moves To Join Invyvid In COVID-19 Prevention
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
Lilly Adds To Radiopharma Arsenal With Option To Buy Radionetics
Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice